ASCO: J&J pads case for new Erleada use with prostate cancer survival data

31st May 2019 Uncategorised 0

Johnson & Johnson’s Erleada may be the follow-up to blockbuster Zytiga, but it’s also ready to go where its predecessor hasn’t gone before.

More: ASCO: J&J pads case for new Erleada use with prostate cancer survival data
Source: fierce